[JAK2 V617F mutation burden and its clinical implications in 415 patients with myeloproliferative neoplasm]

Area of Science:

• Hematology
• Molecular Biology
• Oncology

Background:

• Myeloproliferative neoplasms (MPN) are a group of clonal hematopoietic stem cell disorders.
• The JAK2 V617F mutation is a key driver mutation in MPN, affecting signaling pathways.
• Understanding mutation burden and its clinical implications is crucial for patient management.

Purpose of the Study:

• To quantify the JAK2 V617F mutation burden in MPN patients.
• To investigate the clinical significance of JAK2 V617F mutation burden.
• To correlate mutation burden with specific MPN subtypes and clinical parameters.

Main Methods:

• JAK2 V617F mutation burden was detected using MGB Taqman probes.
• A retrospective study was conducted on 415 MPN patients.
• Clinical data and mutation burden were analyzed.

Main Results:

• JAK2 V617F mutation was detected in 56.9% of MPN patients, with varying prevalence across subtypes (PV: 83.5%, ET: 55.9%, PMF: 41.9%).
• The majority of patients had heterozygous mutations; homozygous mutations were rare.
• Mutation burden was highest in polycythemia vera (PV), followed by essential thrombocythemia (ET) and primary myelofibrosis (PMF).
• Higher mutation burden correlated with increased age and WBC count in PV; WBC count in ET; and WBC count, Hb, and platelet count in PMF.

Conclusions:

• JAK2 V617F mutation burden follows the order PV > ET > PMF.
• Heterozygous mutations are most common.
• Mutation burden is positively associated with age, WBC, Hb, and platelet counts in MPN patients.